

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007476 A1

(51) International Patent Classification⁷: C07D 313/00,
327/02, 417/06, 497/04, 493/04, A61K 31/425, A61P
35/00

(74) Agents: BOETERS, Hans et al.; Boeters & Lieck, Bere-
iteranger 15, 81541 München (DE).

(21) International Application Number:
PCT/EP2003/006066

(22) International Filing Date: 10 June 2003 (10.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
102 32 094.2 15 July 2002 (15.07.2002) DE

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
GESELLSCHAFT FUER BIOTECHNOLOGISCHE
FORSCHUNG MBH (GBF) [DE/DE]; Mascheroder
Weg 1, 38124 Braunschweig (DE).


Published:
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): HOEFLE, Gerhard
[DE/DE]; Alter Weg 12a, 38124 Braunschweig (DE).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: GESELLSCHAFT FÜR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)



(57) Abstract: The invention relates to 5-thiapethylones and 15-disubstituted epothilones according to formula I (I) with the following meanings: X = >C=O or >S=O R¹ = C₁₋₆ alkyl or C₂₋₆ alkenyl R² = H or C₁₋₆ alkyl Y - Z = >C=C< or >C-O-C< (epoxide ring) R³ = H, C₁₋₆ alkyl or C₂₋₆ alkenyl R⁴ = bicycloaryl, bicycloheteroaryl or -C(R⁵) = CH-R⁶, where R⁵ = H or CH₃ and R⁶ = aryl or heteroaryl X not being >C=O if R³ = H.

Gesellschaft für Biotechnologische Forschung mbH (GBF)

5-THIAEPOTHILONES AND 15-DISUBSTITUTED EPOTHILONES


The present invention relates to 5-thiaepothilones and 15-disubstituted epothilones which are 16-membered cytotoxic macrolides of formula I with an application potential in cancer therapy and in the treatment of other instances of cell growth impairment.

Epothilones are well known. They can be obtained by fermenting the myxobacterium *Sorangium cellulosum* (GBF) by semisynthesis (GBF, BMS) by genetic engineering and heterologous expression (Kosan Biosciences), by total synthesis (Danishefsky, Nicolaou, Schinzer, Novartis, Schering).

All the epothilones which have become known so far have the common characteristic of carrying a keto group (X = carbonyl) in position 5 and a hydrogen ($R^3 = H$) on the C15 atom. The present invention relates to epothilones which, in contrast to the known state of the art, exhibit either

- (1) a sulfoxide group for X or
- (2) an alkyl or alkenyl group by way of R^3 on the C15 carbon atom or
- (3) both a sulfoxide group X and an alkyl or alkenyl group as radical R^3 .

The invention also relates to epothilones of the following general formula I:



with the following meanings:

$$X = >C = 0 \text{ or } >S = 0$$

$R^1 = C_{1-6}$ alkyl or C_{2-6} alkenyl

$$R^2 = \text{H or } C_{1-6} \text{ alkyl}$$
$$Y - Z = >C=C< \text{ or } >C-O-C< \text{ (epoxide ring)}$$

$R^3 = H, C_{1-6} \text{ alkyl or } C_{2-6} \text{ alkenyl}$

$$R^4 = \text{bicycloaryl, bicycloheteroaryl or } -C(R^5) = CH-R^6,$$

where

$$R^5 = H \text{ or } CH_3 \text{ and}$$





R^6 = aryl or heteroaryl





X not being $>C=0$ if $R^3 = H$.

A compound of the general formula I with $Z-Y = >C=C<$ can be produced from a compound of formula 1 by aldol reaction with a compound of formula 2. In the following reaction scheme, P represents a protective group common in epothilone chemistry, such as a silyl group. Subsequently, the compound of formula 3 thus obtained is reacted, with ring closure (formation of lactone), to a compound of formula 4.

A compound of the general formula I with $Y-Z = >\underline{C-O-C}<$ (epoxide ring) can be produced by reacting a compound of formula 5 with a compound of formula 6 in an aldol


reaction. The resulting compound of formula 7 can be cyclised after liberating the aldehyde group from the acetal in an aldol reaction, whereupon the lactone thus obtained is subjected to epoxidation in position 12,13.






Below, the invention is further illustrated by two synthesis examples.


Synthesis example Ia: $X = SO$, $R^1, R^2 = CH_3$,

$Z - Y = C=C$, $R^3 = H$, $R^4 =$ 



with $R^5 = CH_3$, $R^6 = 4-(2\text{-methylthiazolyl})$



$(Me_3Si)_2NLi$




P = protective groups, e.g. silyl



HF





Net_3 , DMAP, pyridine



5-thiaepothilone

- 7 -


Synthesis example Ib: $X = C = O$, $R^1, R^2 = CH_3$,



= 15-Methyl epothilone B

CLAIMS

1. Epothilone of the general formula (I):



with the following meanings:

X = >C = O or >S = O and/or

R¹ = C₁₋₆ alkyl or C₂₋₆ alkenyl and/or

R² = H or C₁₋₆ alkyl and/or

Y - Z = >C=C< or >C-O-C< (epoxide ring) and/or

R³ = H, C₁₋₆ alkyl or C₂₋₆ alkenyl and/or

R⁴ = bicycloaryl, bicycloheteroaryl or -C(R⁵) = CH-R⁶,

where

R⁵ = H or CH₃ and

R⁶ = aryl or heteroaryl,

X not being >C=O if R³ = H,

and one, a plurality or all conceivable combinations of the radicals X, R¹, R², R³, R⁴, R⁵, R⁶ and Y - Z

2. Epothilone according to claim 1, where R⁴ is a bicycloaryl or bicycloheteroaryl radical common in epothilone chemistry.
3. Epothilone according to claim 1, where R⁶ is an aryl or heteroaryl radical common in epothilone chemistry.

4. Epothilone according to claim 3, where the heteroaryl radical is a monocyclic 5 or 6-membered heteroaromatic which may exhibit one or a plurality of O and/or N and/or S atoms in the ring.
5. Epothilone according to claim 3, where the aryl radical may be a heteroaromatic with one or a plurality of and in particular 1, 2, 3 or 4 heteroatoms.
6. Agent for cancer therapy and/or treating other instances of cell growth impairment, consisting of or containing one or a plurality of epothilones according to any one of the preceding claims, apart from the usual auxiliary agents.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/06066

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D313/00 C07D327/02 C07D417/06 C07D497/04 C07D493/04
A61K31/425 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 02514 A (BRISTOL-MYERS) 21 January 1999 (1999-01-21) page 64; claims 1,3-5	1,3,6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 October 2003

Date of mailing of the international search report

14/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06066

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9902514	A	21-01-1999	
		AU 731497 B2	29-03-2001
		AU 7972098 A	08-02-1999
		BG 104068 A	29-09-2000
		BR 9810555 A	15-08-2000
		CN 1270589 T	18-10-2000
		EE 200000013 A	15-08-2000
		EP 1019389 A2	19-07-2000
		HU 0103111 A2	29-04-2002
		JP 2002512634 T	23-04-2002
		LT 99153 A , B	25-08-2000
		LV 12569 A	20-11-2000
		LV 12569 B	20-04-2001
		NO 20000076 A	07-01-2000
		NZ 501198 A	28-09-2001
		PL 338003 A1	25-09-2000
		SK 181799 A3	06-08-2001
		TR 200000065 T2	21-11-2000
		US 6605599 B1	12-08-2003
		WO 9902514 A2	21-01-1999
		ZA 9805938 A	10-01-2000